Jan 26, 2026 07:00AM
Nov 19, 2025 08:32AM
Nov 19, 2025 08:30AM
Nov 5, 2025 07:30AM
Oct 21, 2025 08:00AM
Oct 21, 2025 08:00AM
Aug 14, 2025 04:35PM Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
May 13, 2025 07:30AM
Feb 25, 2025 07:00AM
Nov 5, 2024 07:30AM
Aug 7, 2024 06:49AM
Aug 6, 2024 07:30AM
May 2, 2024 06:51AM
May 1, 2024 07:30AM Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
Feb 27, 2024 08:00AM
Feb 27, 2024 08:00AM
Feb 22, 2024 07:00AM
Nov 7, 2023 07:30AM
Aug 1, 2023 07:30AM
Jun 28, 2023 08:31AM
Jun 28, 2023 08:30AM Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
May 15, 2023 07:30AM
May 10, 2023 08:00AM
May 10, 2023 08:00AM
May 1, 2023 07:03AM
May 1, 2023 07:01AM
May 1, 2023 07:00AM
May 1, 2023 07:00AM Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Mar 8, 2023 07:30AM
Mar 8, 2023 07:30AM
Dec 28, 2022 08:01AM
Dec 28, 2022 08:00AM
Dec 28, 2022 08:00AM
Nov 9, 2022 08:00AM
Nov 9, 2022 08:00AM Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
Oct 17, 2022 08:31AM
Oct 17, 2022 08:30AM
Oct 17, 2022 08:30AM
Sep 9, 2022 04:05PM
Sep 9, 2022 04:05PM
Aug 22, 2022 08:05AM
Aug 22, 2022 08:00AM Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
Aug 22, 2022 08:00AM
Aug 9, 2022 08:00AM
Aug 9, 2022 08:00AM
May 4, 2022 08:30AM
May 4, 2022 08:30AM
Apr 7, 2022 08:31AM
Apr 7, 2022 08:30AM Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms
Apr 7, 2022 08:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All